US5908784A
Expired / Lapsed
US
⏱️ 0.0 years remaining
In vitro chondrogenic induction of human mesenchymal stem cells
Assignee: KALLIO PAULI T
•
Filing: 1996-11-15
•
Granted: 1999-06-01
•
Expires: 2016-11-15
Abstract
Abstract Disclosed are a composition of chemically defined components which support the in vitro chondrogenesis of mesenchymal progenitor cells, a method for in vitro chondrogenic induction of such progenitor cells and a method of forming human chondrocytes in vitro from such progenitor cells.
Inventors
- 👤 Brian Johnstone
- 👤 Jung Yoo
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 21:56
CPC Classifications
C; C12; C12N; C12N5/00; C12N5/06; C12N5/0602; C12N5/0652; C12N5/0655; C12N2500/00; C12N2500/05; C12N2500/10; C12N2500/20; C12N2500/24; C12N2500/25; C12N2500/30; C12N2500/34; C12N2500/36; C12N2500/38; C12N2500/90; C12N2501/00; C12N2501/10; C12N2501/15; C12N2501/155; C12N2501/30; C12N2501/38; C12N2501/39; C12N2533/00; C12N2533/50; C12N2533/54
Claims Analysis
Total Claims: 31
Claim 1
Independent Claim
47 words
A composition for the in vitro chondrogenesis of human mesenchymal precursor cells and the in vitro formation of human chondrocytes therefrom, which composition comprises isolated human mesenchymal stem cells condensed into close proximity as a packed cell pellet and at least one chondroinductive agent in contact therewith.
Claim 2
Dependent Claim
47 words
A composition for the in vitro chondrogenesis of human mesenchymal precursor cells and the in vitro formation of human chondrocytes therefrom, which composition comprises isolated human mesenchymal stem cells condensed into close proximity as a packed cell pellet and at least one chondroinductive agent in contact therewith.
Claim 3
Dependent Claim
18 words
The composition of claim 1 wherein the mesenchymal stem cells are isolated, culture expanded human mesenchymal stem cells.
Claim 4
Dependent Claim
17 words
The composition of claim 1 wherein the mesenchymal stem cells are in a chemically defined serum-free environment.
Claim 5
Dependent Claim
37 words
The composition of claim 1 wherein the chondroinductive agent is selected from the group consisting of (i) a glucocorticoid; (ii) a member of the transforming growth factor-β superfamily; and (iii) a component of the collagenous extracellular matrix.
Claim 6
Dependent Claim
10 words
The composition of claim 4 wherein the glucocorticoid is dexamethasone.
Claim 7
Dependent Claim
34 words
The composition of claim 4 wherein the member of the transforming growth factor superfamily is selected from the group consisting of a bone morphogenic protein, TGF-β 1, inhibin A and chondrogenic stimulating activity factor.
Claim 8
Dependent Claim
12 words
The composition of claim 6 wherein the bone morphogenic protein is BMP-4.
Claim 9
Dependent Claim
16 words
The composition of claim 4 wherein the component of the collagenous extracellular matrix is collagen I.
Claim 10
Dependent Claim
16 words
The composition of claim 8 wherein the collagen I is in the form of a gel.
Claim 11
Dependent Claim
16 words
The composition of claim 1 wherein the chondroinductive agent is a combination of dexamethasone and TGF-β1.
Claim 12
Dependent Claim
34 words
A process for producing chondrocytes from mesenchyrnal stem cells by contacting mesenchymal stem cells with a chondroinductive agent in vitro wherein the stern cells are condensed into close proximity as a packed cell pellet.
Claim 13
Dependent Claim
34 words
A process for producing chondrocytes from mesenchyrnal stem cells by contacting mesenchymal stem cells with a chondroinductive agent in vitro wherein the stern cells are condensed into close proximity as a packed cell pellet.
Claim 14
Dependent Claim
18 words
The process of claim 11 wherein the mesenchymal stem cells are isolated, culture expanded human mesenchymal stem cells.
Claim 15
Dependent Claim
17 words
The process of claim 11 wherein the mesenchymal stem cells are in a chemically defined serum-free environment.
Claim 16
Dependent Claim
37 words
The process of claim 11 wherein the chondroinductive agent is selected from the group consisting of (i) a glucocorticoid; (ii) a member of the transforming growth factor-β superfamily; and (iii) a component of the collagenous extracellular matrix.
Claim 17
Dependent Claim
16 words
The process of claim 11 wherein the chondroinductive agent is a combination of dexamethasone and TGF-β1.
Claim 18
Dependent Claim
25 words
The process of claim 11 wherein the step of contacting comprises culturing a pellet of human mesenchymal stem cells in a chemically defined serum-free medium.
Claim 19
Dependent Claim
45 words
The process of claim 16 wherein the chemically defined serum-free medium comprises (1) a chemically defined minimum essential medium; (2) ascorbate or an analog thereof; (3) an iron source; (4) insulin or an insulin-like growth factor; and (5) at least one chondroinductive agent or factor.
Claim 20
Dependent Claim
22 words
The method of claim 11 wherein the cells are cultured with the chondroinductive composition and thereafter placed in a rigid porous vessel.
Claim 21
Dependent Claim
14 words
The method of claim 18 wherein the rigid porous vessel is a ceramic cube.
Claim 22
Dependent Claim
34 words
A process for inducing chondrogenesis in mesenchymal stem cells by contacting mesenchymal stem cells with a chondroinductive agent in vitro wherein the stem cells are condensed into close proximity as a packed cell pellet.
Claim 23
Dependent Claim
34 words
A process for inducing chondrogenesis in mesenchymal stem cells by contacting mesenchymal stem cells with a chondroinductive agent in vitro wherein the stem cells are condensed into close proximity as a packed cell pellet.
Claim 24
Dependent Claim
18 words
The process of claim 20 wherein the mesenchymal stem cells are isolated, culture expanded human mesenchymal stem cells.
Claim 25
Dependent Claim
17 words
The process of claim 20 wherein the mesenchymal stem cells are in a chemically defined serum-free environment.
Claim 26
Dependent Claim
37 words
The process of claim 20 wherein the chondroinductive agent is selected from the group consisting of (i) a glucocorticoid; (ii) a member of the transforming growth factor-β superfamily; and (iii) a component of the collagenous extracellular matrix.
Claim 27
Dependent Claim
16 words
The process of claim 20 wherein the chondroinductive agent is a combination of dexamethasone and TGF-β1.
Claim 28
Dependent Claim
25 words
The process of claim 20 wherein the step of contacting comprises culturing a pellet of human mesenchymal stem cells in a chemically defined serum-free medium.
Claim 29
Dependent Claim
45 words
The process of claim 25 wherein the chemically defined serum-free medium comprises (1) a chemically defined minimum essential medium; (2) ascorbate or an analog thereof; (3) an iron source; (4) insulin or an insulin-like growth factor; and (5) at least one chondroinductive agent or factor.
Claim 30
Dependent Claim
22 words
The method of claim 20 wherein the cells are cultured with the chondroinductive composition and thereafter placed in a rigid porous vessel.
Claim 31
Dependent Claim
14 words
The method of claim 27 wherein the rigid porous vessel is a ceramic cube.
References Cited (Backward Citations)
US5197985A
Cited
US5226914A
Cited
US5486359A
Cited
US5646001A
Cited
US5436151A
Cited
US5466572A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2002-05-31 | 2002-11-30 | 2003-06-01 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2006-05-31 | 2006-11-30 | 2007-06-01 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2010-05-31 | 2010-11-30 | 2011-06-01 | $7700.00 | Window Closed / Lapsed |